Cargando…
Biologics: how far can they go in Crohn’s disease?
Crohn’s disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522383/ https://www.ncbi.nlm.nih.gov/pubmed/36196255 http://dx.doi.org/10.1093/gastro/goac049 |
_version_ | 1784800054391865344 |
---|---|
author | Dunleavy, Katie A Pardi, Darrell S |
author_facet | Dunleavy, Katie A Pardi, Darrell S |
author_sort | Dunleavy, Katie A |
collection | PubMed |
description | Crohn’s disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn’s disease and examines the positioning of medical therapy as emerging biologics break onto the market. |
format | Online Article Text |
id | pubmed-9522383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95223832022-10-03 Biologics: how far can they go in Crohn’s disease? Dunleavy, Katie A Pardi, Darrell S Gastroenterol Rep (Oxf) Review Article Crohn’s disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn’s disease and examines the positioning of medical therapy as emerging biologics break onto the market. Oxford University Press 2022-09-29 /pmc/articles/PMC9522383/ /pubmed/36196255 http://dx.doi.org/10.1093/gastro/goac049 Text en © The Author(s) 2022. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Dunleavy, Katie A Pardi, Darrell S Biologics: how far can they go in Crohn’s disease? |
title | Biologics: how far can they go in Crohn’s disease? |
title_full | Biologics: how far can they go in Crohn’s disease? |
title_fullStr | Biologics: how far can they go in Crohn’s disease? |
title_full_unstemmed | Biologics: how far can they go in Crohn’s disease? |
title_short | Biologics: how far can they go in Crohn’s disease? |
title_sort | biologics: how far can they go in crohn’s disease? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522383/ https://www.ncbi.nlm.nih.gov/pubmed/36196255 http://dx.doi.org/10.1093/gastro/goac049 |
work_keys_str_mv | AT dunleavykatiea biologicshowfarcantheygoincrohnsdisease AT pardidarrells biologicshowfarcantheygoincrohnsdisease |